This observational study aims to understand the genetic and molecular reasons behind childhood liver cancers, including Hepatoblastoma and Hepatocellular Carcinoma. Researchers hope to find better ways to classify these rare cancers based on their biology, how they develop, and who might be more likely to get them. This study is not testing a new treatment. Instead, it involves collecting biological samples like tumor tissue, saliva, or blood, along with medical information, from children who have had liver tumors and their biological parents and siblings. The study will look at genes and how they work in these samples. Success will be measured by how well gene sequencing and gene expression analysis predict recurrence-free survival at two years, and by understanding changes in gene activity during and after chemotherapy.

Study design

This is an observational study planning to include up to 1600 participants, including children with liver tumors and their biological family members.

What's involved

Participants will provide biological samples such as residual tumor tissue, saliva, or blood, along with clinical information about the cancer.

Compensation

Not stated in the trial record.

Follow-up

Researchers will assess recurrence-free survival at two years and the status of genome-wide chromatin accessibility for up to two years after surgical treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.